ReviewCancers2023
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.
Stefano Molica et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it
ReviewCancers2023
Stefano Molica et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.